Messina, Roberta http://orcid.org/0000-0003-4421-0432
Lastarria Perez, Carlo P.
Filippi, Massimo
Goadsby, Peter J.
Article History
Received: 7 May 2020
Revised: 7 June 2020
Accepted: 10 June 2020
First Online: 15 June 2020
Compliance with ethical standards
:
: R. Messina declares, unrelated to this work, compensation for speaking activities from Novartis, Eli Lilly and Teva Pharmaceutical Industries. C. P. Lastarria Pèrez have no conflict of interest related to the publication of this manuscript. M. Filippi declares, unrelated to this work, compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). Prof. Filippi is Editor-in-Chief of the Journal of Neurology. P. J. Goadsby reports unrelated to the work, over the last 36 months, grants and personal fees from Amgen and Eli-Lilly and Company, grant from Celgene, and personal fees from Aeon Biopharma, Alder Biopharmaceuticals, Allergan, Autonomic Technologies Inc., Biohaven Pharmaceuticals Inc., Clexio, Electrocore LLC, Epalex, eNeura, Impel Neuropharma, MundiPharma, Novartis, Santara Therapeutics, Teva Pharmaceuticals, Trigemina Inc., WL Gore, and personal fees from MedicoLegal work, Massachusetts Medical Society, Up-to-Date, Oxford University Press, and Wolters Kluwer; and a patent magnetic stimulation for headache assigned to eNeura without fee.
: The audit was registered with the King’s College Hospital Neurology Department Audit Committee.
: Not applicable.
: The data that support the findings of this study are available upon reasonable request from the corresponding author.
: Not applicable.